Revolution Medicines Inc Stock
Revolution Medicines Inc Stock price
Key metrics
| Market capitalization | $7.59b |
| Enterprise Value | $6.08b |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| EV/Sales (TTM) EV/Sales | 8,221.08 |
| P/S ratio (TTM) P/S ratio | 10,252.58 |
| P/B ratio (TTM) P/B ratio | 4.65 |
| Revenue growth (TTM) Revenue growth | -97.49% |
| Revenue (TTM) Revenue | $740.00k |
Is Revolution Medicines Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
Revolution Medicines Inc Stock Analysis
Analyst Opinions
16 Analysts have issued a Revolution Medicines Inc forecast:
Analyst Opinions
16 Analysts have issued a Revolution Medicines Inc forecast:
Financial data from Revolution Medicines Inc
| Jun '24 |
+/-
%
|
||
| Revenue | 0.74 0.74 |
97%
97%
|
|
| Gross Profit | -9.82 -9.82 |
149%
149%
|
|
| EBITDA | -590 -590 |
89%
89%
|
EBIT (Operating Income) EBIT | -601 -601 |
86%
86%
|
| Net Profit | -519 -519 |
75%
75%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Revolution Medicines Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Revolution Medicines Inc Stock News
Company Profile
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit targets primarily within the RAS and mTOR signaling pathways. The company's principal product candidate is RMC-4630, an inhibitor of SHP2, which is in Phase 1b/2 study for the treatment of RAS-dependent tumors. Its products in preclinical stage include mutant RAS proteins; SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a mTORC1 inhibitor. Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors. The company was founded in 2014 and is headquartered in Redwood City, California.
| Head office | United States |
| CEO | Mark Goldsmith |
| Employees | 378 |
| Founded | 2004 |
| Website | www.revmed.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
